Ratings Healthlead

Equities

End-of-day quote Thailand S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
11.9 ^THB	-0.83%		+2.59%	+14.42%

Apr. 17	Healthlead Public Company Limited Approves Dividend for the Year Ended December 31, 2023, Payable on 10 May 2024	CI
Feb. 29	Healthlead Public Company Limited Announces Management Changes	CI

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Consensus analysts have strongly revised their opinion of the company over the past 12 months.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
With an expected P/E ratio at 38.39 and 32.16 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HEALTHLEAD	+14.42%	87.88M		-
WALGREENS BOOTS ALLIANCE, INC.	-31.79%	15.36B		B-
JD HEALTH INTERNATIONAL INC.	-21.99%	12.45B		B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-22.64%	6.75B		B
YIFENG PHARMACY CHAIN CO., LTD.	+9.74%	6.14B		C
MATSUKIYOCOCOKARA & CO.	-10.91%	6.07B		C+
NAHDI MEDICAL COMPANY	+0.58%	4.78B		D-
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+59.24%	4.53B	-	C
CLICKS GROUP LIMITED	-9.00%	3.81B		B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-12.53%	3.43B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality